Vraylar (Cariprazine): The 2029 Generic Opportunity Window
AbbVie and Gedeon Richter's blockbuster atypical antipsychotic Vraylar (cariprazine hydrochloride, $3.27B in full-year 2024 global net revenue) has a clearly defined future generic window. Its core substance and product patent, US 7,737,142 ('(Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists'), expires on September 17, 2029, inclusive of pediatric exclusivity. No generic cariprazine is commercially selling in the United States today. Major Indian generic manufacturers are actively positioned for entry: Aurobindo Pharma has received tentative FDA approval for its generic capsules, while Zydus Lifesciences, Sun Pharma, and Torrent Pharmaceuticals maintain active Paragraph IV ANDA submissions. Commercial generic entry begins upon patent expiration on September 17, 2029.
What we do
We track expirations like this continuously
This is one drug, picked for today's post. A Portfolio Retainer watches an entire portfolio or compound class on an ongoing basis and flags new matching filings as they publish.